GlassScriptPhysician profile
Guari Mascaro
NPI 1265485213
$1,842.00
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $886 · 2020: $125 · 2021: $548 · 2022: $283.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $435.44 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $364.99 | 2019 | |
| Abbvie INC. | $319.81 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $141.37 | 2022 | |
| Glaxosmithkline, LLC. | $129.49 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $115.68 | 2019 | |
| Lilly USA, LLC | $90.12 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $89.89 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.35 | 2021 | |
| Medtronic, INC. | $23.41 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.76 | 2019 | |
| Allergan, INC. | $19.72 | 2019 | |
| Novo Nordisk INC | $18.58 | 2020 | |
| Vanda Pharmaceuticals INC. | $12.39 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guari Mascaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.